Voltage-dependent calcium channel subunit alpha-2/delta-2 (CACNA2D2)
Homo sapiens — UniProt Q9NY47
Data last refreshed: (UniProt release unknown)
Key facts
Voltage-dependent calcium channel subunit alpha-2/delta-2 (CACNA2D2) is a protein from Homo sapiens identified by UniProt accession Q9NY47, 1150 residues long. MolForge cross-references it against 4 known binders and 497 disease associations.
- UniProt accession: Q9NY47; gene symbol CACNA2D2.
- Organism: Homo sapiens.
- Length: 1150 amino acids.
- Approved drugs acting on it (DrugCentral): Mirogabalin, Pregabalin, Gabapentin and Gabapentin Enacarbil.
- Top disease associations (Open Targets): cerebellar atrophy, developmental delay, and seizures, developmental and epileptic encephalopathy and cardiovascular disease.
- 3D structure: AlphaFold model available.
Target properties
| Protein name | Voltage-dependent calcium channel subunit alpha-2/delta-2 |
|---|---|
| UniProt accession | Q9NY47 |
| Gene | CACNA2D2 |
| Organism | Homo sapiens |
| Length | 1150 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | — |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). Approved drug exists
| Druggability tier | MEDIUM |
|---|---|
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs acting on this target (4)
Approved drugs whose DrugCentral mechanism of action is this protein, most potent first.
Disease associations (497)
Diseases linked to this target (Open Targets).
- cerebellar atrophy, developmental delay, and seizures · score 0.64
- developmental and epileptic encephalopathy · score 0.57
- cardiovascular disease · score 0.46
- generalized anxiety disorder · score 0.39
- fibromyalgia · score 0.38
- Cerebellar atrophy · score 0.37
- Ataxia · score 0.37
- Global developmental delay · score 0.37
- absence epilepsy · score 0.37
- epilepsy · score 0.37
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|---|---|---|---|
| AF-Q9NY47-F1 | alphafold | PREDICTED | 80.93 | — |
Experimental structures are not indexed in MolForge yet — search RCSB PDB for Q9NY47.
Amino-acid sequence (1150 residues)
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
Which approved drugs target CACNA2D2?
DrugCentral lists 4 approved drugs whose mechanism of action is CACNA2D2: Mirogabalin, Pregabalin, Gabapentin and Gabapentin Enacarbil.
Which diseases are associated with CACNA2D2?
The strongest Open Targets associations for CACNA2D2 are cerebellar atrophy, developmental delay, and seizures, developmental and epileptic encephalopathy, cardiovascular disease, generalized anxiety disorder and fibromyalgia.
How long is the CACNA2D2 protein?
The Homo sapiens CACNA2D2 protein (UniProt Q9NY47) is 1150 amino acids long.
Browse: Targets: C · all protein targets A–Z · drugs A–Z.
Sources
- UniProtKB Q9NY47 — name, gene, function, sequence, keywords (CC BY 4.0)
- AlphaFold DB Q9NY47 — predicted 3D structure (CC BY 4.0)
- DrugCentral — approved drugs and mechanism-of-action links (CC BY-SA 4.0)
- Open Targets Platform — disease associations and tractability (CC0)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.